B7-H7

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39 th Annual Meeting, being held from November 6-10, 2024 in Houston, Texas. Building on its deep biological understanding of the B7-H7 axis, NextPoint has developed a series of B7-H7 targeted bispecific CD3 engaging antibodies (BsAbs). These BsAbs are designed to bind both B7-H7 expressed on the surface of tumors cells and CD3 on the surface of T cells to induce potent T cell-mediated cytotoxicity toward B7-H7+ tumors independent of existing ADC/IO approaches. NextPoint’s B7-H7xCD3 BsAb 2:1 bispecific antibody design provides optimized target:CD3 affinity ratio, inactivated Fc effector function and ability to fully evaluate safety preclinically. Due to very limited normal tissue expression, B7-H7xCD3 is safe to administer in a wide dose range. Efficacy data presented at SITC demonstrates potent T cell-mediated cytotoxicity against multiple B7-H7+ tumor cell lines with sub-nanomolar EC50s in addition to induction of complete regressions in most of B7-H7+ tumor bearing mice. “Targeting B7-H7, a novel tumor antigen highly upregulated in cancer cells with restricted normal tissue expression profile, is a new frontier in the treatment of solid tumors. B7-H7 directed T cell engagers have the potential to overcome the complex tumor microenvironment and drive durable anti-tumor responses,” said Tatiana Novobrantseva, PhD, Chief Scientific Officer of NextPoint Therapeutics. "NextPoint’s T cell engagers’ precise activation of T cells in the proximity of B7-H7-positive cells combined with its potent anti-tumor activity in both in vitro and in vivo studies support our vision of developing effective and targeted B7-H7 immunotherapies. Complete regressions in vivo across multiple animal models is an impressive sign of efficacy showing that B7-H7 targeting BsAbs will push the boundaries of cancer treatments and become a powerful tool in our arsenal against a new group of B7-H7 biomarker defined patients with solid malignancies. Armed with tolerability data, NextPoint is rapidly advancing the Investigational New Drug (IND) application for our T cell engager, NPX372. We look forward to advancing this innovative approach into clinical development supported by the B7-H7 biomarker assay to enrich for responders.” Presentation Details: Title: B7-H7-CD3 Bispecific T cell Engaging Antibodies Demonstrate Potent Anti-Tumor Activity In B7-H7+ Preclinical Tumor Models Abstract Number: 1318 Date & Time: Saturday, November 9, 2024, 9:00 a.m.-7:00 p.m. CST Presenters: Matthew Rausch PhD, Director, Molecular Biology R&D, Karishma Vekaria, Research Associate, R&D Location: Exhibit Halls A B About NextPoint Therapeutics NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit nextpointtx.com .

NEWARK, U.S.A. and NANJING, China Nov 4, 2024  — Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-118, an anti-B7H7 antibody, and BSI-120, anti-MICA/B antibody at the Society for Immunotherapy of Cancer to be held from Nov 6 to 10, 2024. “We are thrilled to present two posters of our innovative pipeline at SITC this year, BSI-118 and BSI-120 demonstrate favorable desired biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies” said Mingjiu Chen, Ph.D., Founder and Chief Executive Officer of Biosion, Inc. “We look forward to sharing the key data of these two therapeutic assets with the oncology research community at SITC.” 01 BSI-118, a novel anti-B7H7 antibody antagonizing B7H7-KIR3DL3 signaling pathway without affecting B7H7-TMIGD2 stimulatory signaling pathway Date: Friday,November 8, 2024 & Saturday,November 9, 2024 Location: Level 1 -Exhibit Halls AB(George R. Brown Convention center) 02 02 BSI-120, a fully human anti-MICA/B antibody with enhanced Fc receptor function, prevents MICA/B shedding and reinforces anti-tumor immunity Date: Friday,November 8, 2024 & Saturday,November 9, 2024 Location: Level 1 -Exhibit Halls AB(George R. Brown Convention center) About Biosion Biosion is a global, clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes with immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform. Biosion has 8 global partnerships with 7 clinical stage assets including monoclonal antibody, bispecific antibody and antibody drug conjugates. Biosion has operations in the US, China and Australia. For more information, please visit www.Biosion.com.

中国南京和美国纽瓦克 2024年11月4日 — 博奥信生物技术（南京）有限公司（简称：“博奥信”），一家处于临床阶段的全球化创新生物技术公司，今天宣布将在2024年11月6日-10日举办的癌症免疫治疗学会（SITC）年会上公布抗B7H7抗体BSI-118和抗MICA/B抗体BSI-120的临床前数据。 “我们很高兴能在今年的癌症免疫治疗学会年会向业内同行展示我们创新管线的两项研究成果，BSI-118和BSI-120具有良好的期望生物活性和理化性质，支持启动临床前开发各项工作包括工艺开发和IND申报相关研究。”博奥信创始人、首席执行官陈明久博士表示：“我们期待在SITC会议期间与肿瘤药物开发同仁分享这两项资产的关键数据。” 01 BSI-118，一种拮抗B7H7-KIR3DL3信号通路但不影响B7H7-TMIGD2信号通路的新型抗B7H7抗体 日期：2024.11.8 星期五 & 11.9 星期六 地址：一楼-AB展厅（George R. Brown会议中心） 02 02 BSI-120，一种具有增强的Fc受体功能同时抑制MICA/B脱落并增强抗肿瘤免疫的全人源抗MICA/B抗体 日期：2024.11.8 星期五 & 11.9 星期六 地址：一楼-AB展厅（George R. Brown会议中心） 关于博奥信 博奥信是一家处于临床阶段的全球化创新生物技术公司，致力于应用其专有的抗体技术平台开发创新疗法，使患者在免疫及肿瘤疾病的治疗中获益。成立于2017年，博奥信通过内部专有的H³（高通量，高含量，高效率）抗体发现平台、SynTracer® 高通量抗体内吞筛选平台、Flexibody®双功能抗体技术平台及全球合作建立了一系列创新药物管线。目前共有7项自研产品在中美开进入临床试验阶段，其中Bosakitug（BSI-045B/TQC2731，抗TSLP单抗）正在中美开展针对严重哮喘、慢性鼻窦炎伴鼻息肉和特应性皮炎的临床II期试验。更多公司及管线信息，请访问www.biosion.com。